Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Capmatinib |
| Synonyms | |
| Therapy Description |
Tabrecta (capmatinib) inhibits MET signaling and may induce cell death in tumors overexpressing MET or expressing constitutively activated MET (PMID: 31853265). Tabrecta (capmatinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Capmatinib | Tabrecta | INC280|INC-280|INCB028060|INCB28060|INCB 28060 | MET Inhibitor 59 | Tabrecta (capmatinib) inhibits MET signaling and may induce cell death in tumors overexpressing MET or expressing constitutively activated MET (PMID: 31853265). Tabrecta (capmatinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05567055 | Phase II | Capmatinib | Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations | Withdrawn | 0 | |
| NCT02520752 | Phase I | Midazolam Capmatinib | A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | DNK | BGR | 0 |
| NCT02925104 | Phase I | Capmatinib | A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. | Completed | USA | SWE | NLD | GBR | ESP | DNK | DEU | AUT | 0 |
| NCT03784014 | Phase III | Ceritinib Dabrafenib + Trametinib Capmatinib Durvalumab + Olaparib Nilotinib Futibatinib Trametinib Palbociclib Glasdegib Lapatinib | Molecular Profiling of Advanced Soft-tissue Sarcomas (MULTISARC) | Active, not recruiting | FRA | 0 |
| NCT02019693 | Phase II | Capmatinib | A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer | Completed | USA | 0 |
| NCT01324479 | Phase I | Capmatinib | Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors | Completed | USA | NOR | NLD | ITA | ISR | FRA | ESP | DEU | CAN | AUS | 5 |
| NCT02587650 | Phase II | Ceritinib Capmatinib Regorafenib Entrectinib | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | Terminated | USA | 0 |
| NCT02750215 | Phase II | Capmatinib | A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor | Completed | USA | 0 |
| NCT03040973 | Phase II | Capmatinib + Nazartinib Capmatinib Capmatinib + Gefitinib | Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments. | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | CAN | BEL | 2 |
| NCT04427072 | Phase III | Docetaxel Capmatinib | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III) | Completed | NLD | ITA | FRA | ESP | DEU | BRA | BEL | 3 |
| NCT04323436 | Phase II | Capmatinib + Spartalizumab Capmatinib | Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | 2 |
| NCT04817956 | Phase II | Ceritinib Melphalan Cobimetinib + Vemurafenib Alectinib Pemigatinib Entrectinib Bortezomib Dostarlimab-gxly Atezolizumab Alpelisib Atezolizumab + Bevacizumab Olaparib Selpercatinib Capmatinib Dactinomycin Dabrafenib + Trametinib Vismodegib Niraparib Imatinib Pertuzumab/trastuzumab/hyaluronidase-zzxf | Improving Public Cancer Care by Implementing Precision Medicine in Norway (IMPRESS-N) | Recruiting | NOR | 0 |
| NCT02626234 | Phase I | Capmatinib | A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors | Completed | USA | ITA | GRC | GBR | ESP | CZE | BEL | AUT | 0 |
| NCT02468661 | Phase I | Capmatinib Capmatinib + Erlotinib Erlotinib Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | Terminated | USA | NLD | ITA | FRA | ESP | DEU | BEL | 3 |
| NCT02414139 | Phase II | Capmatinib | Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (Geometry Mono-1) | Completed | USA | SWE | NOR | NLD | LBN | ITA | ISR | GBR | FRA | ESP | DEU | BEL | AUT | ARG | 6 |
| NCT04926831 | Phase II | Capmatinib | Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (Geometry-N) | Completed | USA | 0 |
CKB BOOST